Drug Information

Drug General Information
Drug ID
D0D1YY
Former ID
DIB006282
Drug Name
IGN-2098
Drug Type
Small molecular drug
Indication Duodenal ulcers [ICD10:K25-K27] Discontinued in Phase 2 [544900]
Company
Ikeda Mohando Co Ltd
Formula
C22H32Cl2N4O2
Canonical SMILES
n1c(=O)c(c([nH]c1NC/C=C\COc1cc(CN2CCCCC2)ccc1)C)C.Cl.Cl
CAS Number
CAS 126868-88-0
PubChem Compound ID
6443221
Target and Pathway
Target(s) Histamine H2 receptor Target Info Antagonist [526772]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gastric acid secretion
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Histamine H2 receptor mediated signaling pathway
PathWhiz Pathway Intracellular Signalling Through Histamine H2 Receptor and Histamine
Gastric Acid Production
Reactome Histamine receptors
G alpha (s) signalling events
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Secretion of Hydrochloric Acid in Parietal Cells
GPCR ligand binding
GPCR downstream signaling
References
Ref 544900Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001447)
Ref 526772Effects of IGN-2098, a new histamine H2-receptor antagonist, on gastric secretion and gastric and duodenal lesions induced in rats. Comparison with roxatidine. Nihon Yakurigaku Zasshi. 1992 Mar;99(3):167-80.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.